Tag: neuroendocrine tumor treatments

NET Webinar, November 21, 2019

Surgical Management of Neuroendocrine Tumors, November 21 Webinar for Patients and Caregivers

November 13, 2019

You’re invited to participate in a Neuroendocrine Tumor Awareness Month Webinar on November 21 from 7 to 9 pm, Eastern Time, presented by the American Association of Endocrine Surgeons (AAES). Four national experts will discuss the surgical management…

READ MORE
Luncheon with the Experts, NYC, May 2014

Luncheon with the Experts in New York City — Carcinoid and Neuroendocrine Tumor Patients Are Invited!

April 13, 2014

 

The Big Apple Noids support group invites you to join fellow carcinoid and neuroendocrine tumor (NET) patients and three medical experts for lunch on Sunday, May 4 from 12:30 to 3:30 pm in a private dining room at Dorrian’s restaurant in Manhattan…

READ MORE
Notch 1 Signaling in NETs, Chen, Kunnimalaiyaan

Treating Neuroendocrine Tumors: New Patent Awarded

December 31, 2012

Herbert Chen, MD, and Muthusamy Kunnimalaiyaan, Ph.D., of the University of Wisconsin School of Medicine and Public Health in Madison, have received a patent (8,338,482) for a “Modulating Notch1 Signaling Pathway for Treating Neuroendocrine

READ MORE
Ebrahim S. Delpassand, MD, FACNM

FDA Approves Amendment for PRRT Clinical Trial in Texas

August 2, 2012

BREAKING NEWS:  The Food and Drug Administration (FDA) has just approved the RadioIsotope Therapy of America (RITA) Foundation’s amendment to the Investigational New Drug (IND) protocol for intra-hepatic artery administration of Lu-177 Octreotate

READ MORE
Siemens’ Biograph mMR system

Up-to-the-Minute: News for the Carcinoid and Neuroendocrine Tumor Community

June 12, 2011

The first device that simultaneously performs PET and MRI scans, a new alpha-emitter-based therapy for NET cancer patients with progressive therapy-resistant tumors, the first–ever randomized virtual clinical trial, over 100  abstracts on carcinoid

READ MORE
Novartis logo

Breaking News: FDA Approves Treatment for pNET Patients

May 5, 2011

For the first time in nearly three decades, there is a new treatment for pancreatic neuroendocrine tumor patients!  The Food and Drug Administration (FDA) today announced its approval of Afinitor© for pNET patients.  This is a milestone for the carcinoid/NET…

READ MORE
GlucoMedix

RadioMedix $2.8 Million Grant from Texas Emerging Technology Fund to Result in New Products that Benefit Carcinoid and Neuroendocrine Cancer Patients

March 23, 2011

Two innovative products that will enable users to generate and label PET radiotracers on-site at a significantly reduced cost will be developed by RadioMedix, Inc. with a $2.8 million grant from the Texas Emerging Technology Fund.  According to Ebrahim

READ MORE